Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.

Souda S, Gaseitsiwe S, Georgette N, Powis K, Moremedi D, Iketleng T, Leidner J, Moffat C, Ogwu A, Lockman S, Moyo S, Mmalane M, Musonda R, Makhema J, Essex M, Shapiro R.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):572-7. doi: 10.1097/QAI.0b013e31829308f8.

2.

Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.

Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3011-9. doi: 10.1128/AAC.06337-11. Epub 2012 Mar 5.

3.

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.

Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M.

Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33. doi: 10.1128/AAC.05599-11. Epub 2011 Dec 19.

4.

Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.

Bazzoli C, Bénech H, Rey E, Retout S, Salmon D, Duval X, Tréluyer JM, Mentré F; COPHAR2-ANRS 111 Study Group.

Antimicrob Agents Chemother. 2011 Jul;55(7):3423-31. doi: 10.1128/AAC.01487-10. Epub 2011 May 16.

5.

Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.

Paintsil E, Dutschman GE, Hu R, Grill SP, Wang CJ, Lam W, Li FY, Ghebremichael M, Northrup V, Cheng YC.

Antimicrob Agents Chemother. 2011 Feb;55(2):895-903. doi: 10.1128/AAC.01303-10. Epub 2010 Nov 15.

6.

Zidovudine and Lamivudine for HIV Infection.

Anderson PL, Rower JE.

Clin Med Rev Ther. 2010;2:a2004.

7.

Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.

Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.

8.

Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.

Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, Lou Y, Yuen GJ, Min SS, Guerini EM.

Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8. doi: 10.1128/AAC.01000-08. Epub 2009 Feb 2.

9.

Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.

Hurwitz SJ, Asif G, Kivel NM, Schinazi RF.

Antimicrob Agents Chemother. 2008 Dec;52(12):4241-50. doi: 10.1128/AAC.00054-08. Epub 2008 Oct 6.

10.

Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro.

Anderson PL, King T, Zheng JH, MaWhinney S.

J Antimicrob Chemother. 2008 Oct;62(4):738-45. doi: 10.1093/jac/dkn247. Epub 2008 Jun 20.

11.

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.

van Praag RM, van Weert EC, van Heeswijk RP, Zhou XJ, Sommadossi JP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM.

Antimicrob Agents Chemother. 2002 Mar;46(3):896-9.

12.

Supplemental Content

Support Center